Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) had its price objective trimmed by HC Wainwright from $46.00 to $40.00 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
A number of other research firms also recently commented on ZNTL. Stifel Nicolaus decreased their target price on Zentalis Pharmaceuticals from $36.00 to $32.00 and set a buy rating on the stock in a research report on Wednesday. Wedbush lifted their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a neutral rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $37.14.
Check Out Our Latest Stock Report on ZNTL
Zentalis Pharmaceuticals Stock Up 1.0 %
Shares of NASDAQ ZNTL traded up $0.12 during midday trading on Wednesday, hitting $12.43. The company had a trading volume of 1,022,881 shares, compared to its average volume of 783,921. The firm has a market capitalization of $882.65 million, a price-to-earnings ratio of -2.74 and a beta of 1.82. Zentalis Pharmaceuticals has a twelve month low of $9.56 and a twelve month high of $31.46. The business has a 50-day simple moving average of $13.70 and a two-hundred day simple moving average of $13.43.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter in the previous year, the business posted ($1.07) earnings per share. On average, equities analysts forecast that Zentalis Pharmaceuticals will post -3.72 EPS for the current year.
Insider Activity
In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the firm's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares of the company's stock, valued at approximately $5,164,576.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.10% of the company's stock.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Several hedge funds have recently made changes to their positions in ZNTL. China Universal Asset Management Co. Ltd. lifted its position in Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company's stock worth $36,000 after buying an additional 1,030 shares during the period. ProShare Advisors LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock worth $243,000 after acquiring an additional 1,274 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of Zentalis Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company's stock worth $91,000 after acquiring an additional 1,519 shares during the last quarter. Arizona State Retirement System grew its holdings in Zentalis Pharmaceuticals by 20.2% in the third quarter. Arizona State Retirement System now owns 14,046 shares of the company's stock valued at $282,000 after purchasing an additional 2,363 shares during the period. Finally, Quest Partners LLC acquired a new position in Zentalis Pharmaceuticals during the fourth quarter worth approximately $38,000.
Zentalis Pharmaceuticals Company Profile
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Further Reading
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
